Valuation : Amicus Therapeutics, Inc.

Market Cap 4.55B 3.92B 3.68B 3.36B 6.31B 433B 6.35B 43.59B 16.96B 220B 17.08B 16.71B 727B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.05B 3.8B 3.47B 6.51B 447B 6.56B 45.01B 17.51B 227B 17.64B 17.26B 751B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+0.91%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.6
Extreme 7.605
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
27/4/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/4/26 Issuer sale

Director

395,940 0.1261%
27/4/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+90.91%+10.19% 4.55B
-1.23%-1.91%+0.98%+17.94% 50.47B
-1.89%-3.65%+415.71%+500.12% 44.56B
-0.39%+0.19%+41.91%+17.12% 43.08B
-2.40%-3.91%+7.65%+72.22% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.68%-4.81%+24.68%+118.37% 16.77B
+6.63%+4.64% - - 16.28B
+0.25%-0.98%+11.63%+27.62% 14.58B
-2.15%-4.05%+77.66%+38.52% 13.92B
Average -0.33%-1.09%+76.61%+94.33% 27.91B
Weighted average by Cap. -0.82%-1.03%+88.97%+119.71%

Financials

2024 2025
Net sales 528M 455M 427M 390M 732M 50.27B 738M 5.06B 1.97B 25.49B 1.98B 1.94B 84.4B 634M 546M 513M 468M 879M 60.34B 886M 6.08B 2.36B 30.6B 2.38B 2.33B 101B
Net income -56.11M -48.31M -45.36M -41.41M -77.78M -5.34B -78.34M -537M -209M -2.71B -211M -206M -8.96B -27.11M -23.34M -21.92M -20.01M -37.58M -2.58B -37.85M -260M -101M -1.31B -102M -99.58M -4.33B
Net Debt 194M 167M 157M 143M 269M 18.43B 270M 1.86B 722M 9.35B 727M 711M 30.94B 149M 128M 120M 110M 206M 14.16B 208M 1.43B 555M 7.18B 559M 547M 23.78B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock